<unk>  is an antineoplastic agent that is FDA approved for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole, progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic, advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib, renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery and tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA).   Common adverse reactions include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.
Everolimus
Ridaforolimus
Sunitinib
Bosutinib
Ceritinib
Panitumumab
Neratinib
Gilteritinib